clindamycin phosphat pfizer i.v./i.m. 300 mg soluzione iniettabile
pfizer ag - clindamycinum - soluzione iniettabile - clindamycinum 300 mg ut clindamycini phosphas, dinatrii edetas, natrii hydroxidum q.s. ad ph, alcohol benzylicus 18 mg, aqua ad iniectabile ad solutionem pro 2 ml corresp. natrium 17.92 mg. - malattie infettive - synthetika
clindamycin phosphat pfizer i.v./i.m. 600 mg soluzione iniettabile
pfizer ag - clindamycinum - soluzione iniettabile - clindamycinum 600 mg ut clindamycini phosphas, dinatrii edetas, natrii hydroxidum q.s. ad ph, alcohol benzylicus 36 mg, aqua ad iniectabile ad solutionem pro 4 ml corresp. natrium 35.84 mg. - malattie infettive - synthetika
ibrance 75 mg capsule rigide
pfizer ag - palbociclibum - capsule rigide - palbociclibum 75 mg, cellulosum microcristallinum, lactosum monohydricum 55.775 mg, carboxymethylamylum natricum a, silica colloidalis anhydrica, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 172 (flavum), e 171, drucktinte: lacca, e 171, ammoniae solutio 28 per centum, propylenglycolum, simeticonum, pro capsula, natrium 1.28 mg. - carcinoma della mammella - synthetika
ibrance 100 mg capsule rigide
pfizer ag - palbociclibum - capsule rigide - palbociclibum 100 mg, cellulosum microcristallinum, lactosum monohydricum 74.367 mg, carboxymethylamylum natricum a, silica colloidalis anhydrica, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 172 (flavum), e 171, drucktinte: lacca, e 171, ammoniae solutio 28 per centum, propylenglycolum, simeticonum, pro capsula, natrium 1.71 mg. - carcinoma della mammella - synthetika
ibrance 125 mg capsule rigide
pfizer ag - palbociclibum - capsule rigide - palbociclibum 125 mg, cellulosum microcristallinum, lactosum monohydricum 92.958 mg, carboxymethylamylum natricum a, silica colloidalis anhydrica, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 172 (flavum), e 171, drucktinte: lacca, e 171, ammoniae solutio 28 per centum, propylenglycolum, simeticonum, pro capsula, natrium 2.13 mg. - carcinoma della mammella - synthetika
dalacin c 150 mg capsule rigide
pfizer ag - clindamycinum - capsule rigide - clindamycinum 150 mg ut clindamycini hydrochloridum, maydis amylum, talcum, magnesii stearas, lactosum monohydricum max. 224.13 mg, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - malattie infettive - synthetika
dalacin c 300 mg capsule rigide
pfizer ag - clindamycinum - capsule rigide - clindamycinum 300 mg ut clindamycini hydrochloridum, maydis amylum, talcum, magnesii stearas, lactosum monohydricum max. 283.27 mg, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - malattie infettive - synthetika
clindamycin pfizer 150 mg capsule rigide
pfizer ag - clindamycinum - capsule rigide - clindamycinum 150 mg ut clindamycini hydrochloridum, maydis amylum, talcum, magnesii stearas, lactosum monohydricum max. 224.13 mg, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - malattie infettive - synthetika
clindamycin pfizer 300 mg capsule rigide
pfizer ag - clindamycinum - capsule rigide - clindamycinum 300 mg ut clindamycini hydrochloridum, maydis amylum, talcum, magnesii stearas, lactosum monohydricum max. 283.27 mg, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - malattie infettive - synthetika
xalkori 200 mg capsule rigide
pfizer ag - crizotinibum - capsule rigide - crizotinibum 200 mg, silica colloidalis anhydrica, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 0.84 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, kalii hydroxidum, e 172 (nigrum), pro capsula. - onkologikum - synthetika